Daiichi Sankyo Company, Limited (DSKYF)
| Market Cap | 33.50B -15.7% |
| Revenue (ttm) | 14.73B +17.0% |
| Net Income | 1.91B +7.3% |
| EPS | 0.96 +2.2% |
| Shares Out | n/a |
| PE Ratio | 18.96 |
| Forward PE | n/a |
| Dividend | 0.63 (3.50%) |
| Ex-Dividend Date | Mar 30, 2027 |
| Volume | 29,789 |
| Open | 18.14 |
| Previous Close | 17.64 |
| Day's Range | 18.14 - 18.14 |
| 52-Week Range | 13.85 - 25.75 |
| Beta | -0.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injec... [Read more]
Financial Performance
In fiscal year 2026, Daiichi Sankyo Company's revenue was 2.12 trillion, an increase of 12.55% compared to the previous year's 1.89 trillion. Earnings were 279.73 billion, a decrease of -5.42%.
Financial numbers in JPY Financial StatementsNews
IDEL, Daiichi Sankyo Team Up To Test Multi-Drug Conjugate For Solid Tumors
(RTTNews) - iDEL Therapeutics said Monday it entered multi-year global research collaboration with Daiichi Sankyo Company, Ltd. (DSNKY) to evaluate a multi-drug conjugate for selected solid tumors.
Daiichi Sankyo Company Earnings Call Transcript: Q2 2027
Q2 revenue rose 19.7% to JPY 1,167.2bn and core operating profit rose 46.9%, led by Enhertu and Datroway; FY 2026 guidance is unchanged. CMO costs, late-year seasonality and upcoming clinical readouts shape the outlook.
Daiichi Sankyo Company Quarterly report: Q2 2027
Daiichi Sankyo Company has published its Q2 2027 quarterly earnings report on October 30, 2026.
Daiichi Sankyo Company Slides: Q2 2027
Daiichi Sankyo Company has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 30, 2026.
Daiichi Sankyo H1 Profit Rises 16% As Cancer Drugs Lift Revenue; Backs FY26 Outlook
(RTTNews) - Friday, Daiichi Sankyo Co., Ltd. (DSKYF) reported strong first-half profit and revenue, supported by growth in cancer medicines Enhertu and Datroway and favourable currency movements.
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026. “Strong revenue growth continues in the second quar...
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union
MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination thera...
AstraZeneca, Daiichi Sankyo's Enhertu Wins First EU Approval In Early Breast Cancer Setting
(RTTNews) - On Tuesday, AstraZeneca (AZN) and Daiichi Sankyo (4568.T) said the European Commission approved Enhertu in the European Union, or EU as a standalone treatment after surgery for adults with...
Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO.
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration with Summit Therapeutics to test their cancer drug, Datroway, in combination with Summit's ivonescimab across multiple tum...
Merck, Daiichi Sankyo withdraw US application for lung cancer drug
Merck and Daiichi Sankyo have voluntarily withdrawn their US application seeking accelerated approval for their experimental lung cancer therapy, the drugmakers said on Friday.
Malaysia's IHH's unit appeals Tokyo court's rejection of Daiichi Sankyo damages claim
Malaysia's IHH Healthcare said on Thursday its subsidiary has appealed a Tokyo court's dismissal of its damages claim against Daiichi Sankyo over the unit's acquisition of a stake in India's Fortis ...
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dos...
TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
TOKYO--(BUSINESS WIRE)--The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus curre...
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization.
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company's o...
Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
TOKYO--(BUSINESS WIRE)--Enhertu Showed Statistically Significant & Clinically Meaningful PFS Improvement as First-Line Treatment of Patients with HER2 Mutant Advanced NSCLC.
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK...
Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026. “Daiichi Sankyo delivered strong revenue growth in the fi...
Daiichi Sankyo Company Earnings Call Transcript: Q1 2027
Revenue surged 21% YoY in Q1 FY 2026, driven by ENHERTU and DATROWAY, but operating profit fell due to restructuring costs and inventory valuation losses. FY 2026 guidance was raised on strong U.S. sales and yen depreciation, with ongoing investments in operational excellence.
Daiichi Sankyo Company Quarterly report: Q1 2027
Daiichi Sankyo Company has published its Q1 2027 quarterly earnings report on July 31, 2026.
Daiichi Sankyo Company Slides: Q1 2027
Daiichi Sankyo Company has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 31, 2026.
Trump Plans 100% Tariff on Generic Drugs From 2028
President Donald Trump said generic drug manufacturers will have two years to move production to the US or face a 100% import duty. Bloomberg's Mica Soellner reports on what could come next.
AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports
Drugmakers AstraZeneca and Daiichi Sankyo are nearing an agreement with the UK's pricing regulator for their breast cancer treatment Enhertu, Bloomberg News reported on Wednesday, citing multiple pe...
Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clin...